Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Completed · Phase 1, Phase 2 · NCT02315326
Conditions: Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
At a glance
- Research payments reported, 2025
- $222,544
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 93
About the trial
- Sponsor
- Memorial Sloan Kettering Cancer Center (with Pharmacyclics LLC., Janssen Biotech, Inc.)
- Tested
- Ibrutinib (drug), HD- Methotrexate (MTX) (drug), Rituximab + HD- Methotrexate (MTX) (drug), procarbazine (drug)
- Dates
- Started 2014-12-08; completion 2026-01-28
- Results posted
- Not yet
The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the established first-line chemotherapy regimen rituximab, methotrexate, vincristine, and procarbazine (R-VMP) in order to further refine the first-line induction therapy for PCNSL, as observed by a superior CRR (complete response rate) (ARM D RECRUITING ONLY)
From ClinicalTrials.gov, last updated 2026-02-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $222,544 in research payments for this study in 2025 (1 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan-Kettering Cancer Center $222,544
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.